Exome Asset Management LLC Buys New Stake in BioNTech SE (NASDAQ:BNTX)

Exome Asset Management LLC purchased a new stake in BioNTech SE (NASDAQ:BNTX) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 34,552 shares of the company’s stock, valued at approximately $4,104,000. BioNTech comprises 2.7% of Exome Asset Management LLC’s investment portfolio, making the stock its 10th biggest holding.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BNTX. Slow Capital Inc. lifted its position in shares of BioNTech by 12.0% in the 2nd quarter. Slow Capital Inc. now owns 51,080 shares of the company’s stock worth $4,105,000 after acquiring an additional 5,467 shares during the period. Van ECK Associates Corp lifted its position in BioNTech by 1.9% in the second quarter. Van ECK Associates Corp now owns 119,901 shares of the company’s stock worth $9,635,000 after purchasing an additional 2,192 shares during the period. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV boosted its stake in BioNTech by 41.4% during the second quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV now owns 20,500 shares of the company’s stock worth $1,647,000 after buying an additional 6,000 shares in the last quarter. TD Asset Management Inc increased its holdings in BioNTech by 6.1% in the 2nd quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after buying an additional 435 shares during the period. Finally, Candriam S.C.A. raised its stake in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after buying an additional 418,695 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BNTX shares. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and lifted their target price for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. HSBC upped their price objective on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. TD Cowen lowered their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. Wells Fargo & Company started coverage on BioNTech in a report on Wednesday. They set an “overweight” rating and a $170.00 price objective for the company. Finally, Berenberg Bank assumed coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and a consensus price target of $140.76.

BioNTech Stock Performance

Shares of BNTX stock opened at $120.38 on Friday. The stock has a market cap of $28.62 billion, a PE ratio of -57.32 and a beta of 0.22. The stock has a 50-day moving average of $113.86 and a 200-day moving average of $100.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the prior year, the firm earned $0.73 earnings per share. The business’s quarterly revenue was up 38.9% on a year-over-year basis. As a group, sell-side analysts expect that BioNTech SE will post -3.72 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.